Sign In
Buy MIRM
$105.95
-6.64 (-5.90%)
At Close: Jul 31, 2026
MIRM's Q3 Earnings & Revenues Beat Estimates, 2025 View Tightened
12:31pm, Wednesday, 05'th Nov 2025
Mirum posts third-quarter profit and stronger revenues on surging Livmarli demand, while tightening its 2025 sales outlook.
Mirum Pharmaceuticals, Inc. (MIRM) Q3 2025 Earnings Call Transcript
06:56pm, Tuesday, 04'th Nov 2025
Mirum Pharmaceuticals, Inc. ( MIRM ) Q3 2025 Earnings Call November 4, 2025 4:30 PM EST Company Participants Andrew McKibben - Senior Vice President, Strategic Finance & Investor Relations Christopher
Mirum Pharmaceuticals, Inc. (MIRM) Surpasses Q3 Earnings and Revenue Estimates
06:11pm, Tuesday, 04'th Nov 2025
Mirum Pharmaceuticals, Inc. (MIRM) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.1 per share. This compares to a loss of $0.3 per share a ye
Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
04:01pm, Tuesday, 04'th Nov 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update.
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
04:05pm, Monday, 03'rd Nov 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences.
Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
04:02pm, Tuesday, 28'th Oct 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025.
Will Livmarli Continue to Drive Mirum's Top Line in Q3 Earnings?
12:01pm, Tuesday, 14'th Oct 2025
MIRM's Livmarli remains its dominant growth engine and is expected to have boosted its top line in the third quarter.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:45pm, Friday, 10'th Oct 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick?
11:45am, Tuesday, 23'rd Sep 2025
CorMedix and Mirum Pharmaceuticals are advancing niche therapies with strong launches, rising sales and strategic acquisitions shaping their growth.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06:45pm, Wednesday, 10'th Sep 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals, Inc. (MIRM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
11:13am, Monday, 08'th Sep 2025
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 8:30 AM EDT Company Participants Christopher Peetz - CEO & Director Conference Call
Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study
08:00am, Monday, 08'th Sep 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the completion of enrollment in the Phase 2b VISTAS study of volixibat, an investigational oral IBAT in
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
04:02pm, Wednesday, 27'th Aug 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences.
Mirum Pharmaceuticals: Q2 Results Continue To Show Positive Momentum
09:48am, Monday, 11'th Aug 2025
Mirum Pharmaceuticals continues to outperform, beating revenue and earnings expectations for two consecutive quarters and raising guidance. Livmarli, Mirum's flagship drug, is driving strong revenue g
MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View
12:20pm, Thursday, 07'th Aug 2025
Mirum surges after second-quarter earnings and revenues top estimates, driven by Livmarli growth and a raised 2025 outlook.
